Meeting
2013 ASCO Annual Meeting
Regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing following sorafenib: An ongoing randomized, double-blind, phase III trial.
Authors
Ann-Lii Cheng
National Taiwan University Hospital, Taipei, Taiwan
Ann-Lii Cheng , Richard S. Finn , Masatoshi Kudo , Josep M. Llovet , Shukui Qin , Marie-Aude Le Berre , Heiko Krissel , Jordi Bruix
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Clinical Trial Registration Number
NCT01774344
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS4163)
DOI
10.1200/jco.2013.31.15_suppl.tps4163
Abstract #
TPS4163
Poster Bd #
34A
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
RESORCE: An ongoing randomized, double-blind, phase III trial of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing on sorafenib (SOR).
First Author: Jordi Bruix
Poster
2017 ASCO Annual Meeting
Efficacy of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial according to alpha-fetoprotein (AFP) and c-Met levels as predictors of poor prognosis.
First Author: Michael Teufel
Poster
2017 Gastrointestinal Cancers Symposium
Survival by pattern of tumor progression during prior sorafenib (SOR) treatment in patients with hepatocellular carcinoma (HCC) in the phase III RESORCE trial comparing second-line treatment with regorafenib (REG) or placebo.
First Author: Jordi Bruix
Poster
2016 ASCO Annual Meeting
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).
First Author: Andrew X. Zhu